Abstract: Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand (CD95L) is a cytokine, which needs to trimerize to mediate a cell death signal. Mega-Fas-Ligand, now referred to as APO010, is a synthetic hexameric CD95 agonist that exhibits strong antitumor activity in various tumor models. Here, we studied the effects of APO010 in human glioma models in vitro and in vivo. Compared with a cross-linked soluble CD95L or a CD95-agonistic antibody, APO010 exhibited superior activity in glioma cell lines expressing CD95 and triggered caspase-dependent cell death. APO010 reduced glioma cell viability in synergy when combined with temozolomide. The locoregional administration of APO010 induced glioma cell death in vivo and prolonged the survival of tumor-bearing mice. A further exploration of APO010 as a novel antiglioma agent is warranted. 
Introduction
Death ligands of the tumor necrosis factor (TNF) family have been shown to induce apoptosis in a variety of human tumor models. 1 The prototypic death ligand, CD95L, was identified as a natural ligand of receptor molecules previously recognized to be activated by cytolytic antibodies referred to as CH11 anti-Fas 2 or anti-APO-1 3 in humans or Jo2 in mice. 4 Agonistic antibodies to CD95 5, 6 as well as CD95L 7 were cytolytic for malignant glioma cells in vitro. In vivo applications were initially not further pursued because of hepatotoxicity, despite some preliminary evidence of the feasibility at least of a local application. 8, 9 CD95 is the principal receptor for CD95L, although a soluble decoy receptor, DcR3, has also been identified and may act to protect glioma cells from apoptosis.
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Given the toxicity associated with CD95 agonism, Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) became the most promising death ligand for an application in the clinic, including malignant glioma. [11] [12] [13] Apo2L/TRAIL interacts with at least five receptors: death receptor (DR)4/TRAIL-R1 and DR5/TRAIL-R2 transmit an apoptotic signal whereas DcR1/TRAIL-R3 and DcR2/TRAIL-R4 do not.
Further, osteoprotegerin is a low affinity soluble receptor for Apo2L/TRAIL of unknown physiological significance. 14 However, even Apo2L/TRAIL was not untoxic to normal cells, and it became clear that efficacy and tolerability of Apo2L/TRAIL depend on specific modifications of the recombinant cytokine.
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A natural human Apo2L/TRAIL referred to as Apo2L.0 containing amino acids 114-281 was presumed to be well-tolerated while retaining tumor activity. Both CD95L and Apo2L/TRAIL recruit Fas-associated death domain protein (FADD) to their death-promoting receptors and consecutively trigger caspase-mediated cell death. In the ongoing search for a potent death ligand with an acceptable safety profile, Holler and colleagues (2003) developed the "Mega-Fas-Ligand", a hexameric protein consisting of two CD95L extracellular domain trimers and the collagen domain of adiponectin ACRP30. 17 This molecule is now known as APO010. Here we characterize the cytolytic properties of APO010 on human glioma cells in vitro and in vivo and compare its potency to a cross-linked soluble CD95L and an agonistic anti-CD95 antibody.
Materials and Methods

Materials and cell lines
The human malignant glioma cell lines LN-308, LNT-229 (T for Tübingen To stably overexpress CD95, LN-308 cells were transfected with the BCMGS.neo expression vector containing the cDNA for CD95 using Metafectene Pro (Biontex, Martinsried, Germany). The generation of the expression vector has been described .
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The LN-308.CD95 transfectants and the LN-308.neo control cells were selected with G418 (500 µg/ml) and LN-308.CD95 cells were further subcloned. Primary glioblastoma cells were established from freshly resected tumors, cultured in monolayers, and used between passages 4 and 9. 20 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 mg/ml).
DEVD-amc and zVAD-fmk were obtained from Bachem (Heidelberg, Germany).
Propidium iodide (PI) was purchased from Sigma (St Louis, MO, USA).
Temozolomide was obtained from Schering Plough (Kenilworth, NJ). APO010 was provided by Topotarget (Copenhagen, Denmark).
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O 6 -Benzylguanine (O6BG) was a gift from Bernd Kaina, Mainz, Germany. 21 sCD95L and enhancer were obtained from Alexis (Grünberg, Germany). sCD95L consists of the extracellular domain of human CD95L (amino acid 103-281) fused at the N-terminus to a linker peptide (26 amino acids) and a FLAG-tag. The cross-linking enhancer increases the biological activity by ~50-fold. sCD95L and enhancer were used at a ratio of 1:5. In the following, the term sCD95L stands for the combination of sCD95L and the enhancer molecule. An agonistic antibody to CD95 (clone CH11) was from Upstate (Lake Placid, NY).
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RNA silencing
To silence endogenous CD95 expression, U87MG and LNT-229 cells were transiently transfected with 50 nM HS_FAS_7 HP validated small interfering RNA (siRNA) targeting CD95 from Qiagen (Hilden, Germany; Cat No. SI02654463; sense strand 5`-GGAGUACACAGACAAAGCCTT-3`). All Stars non-silencing siRNA from Qiagen (Hilden, Germany; Cat No. 1027280) was used as a negative control. Glioma cells were seeded in 24 well plates and 24 h later transfected with siRNA using Metafectene Pro (Biontex, Martinsried, Germany). The extent of gene silencing was verified by analysis of CD95 expression on the cell surface by flow cytometry.
DEVD-amc cleavage assay
The cells were seeded in 96 well plates, treated as indicated, lysed in 25 mM TrisHCl, pH 8.0, 60 mM NaCl, 2.5 mM EDTA, 0.25% Nonidet-P40 for 10 min and DEVDamc was added at 12.5 mM. Caspase activity was assessed by fluorescence using a Berthold Mithras fluorimeter (Berthold Technologies, Karlsbad, Germany) at 355 nm excitation and 475 nm emission wavelengths.
Flow cytometry for CD95 expression
Adherent glioma cells were detached using Accutase (PAA, Wien, Austria) and blocked with 2% fetal calf serum in phosphate-buffered saline (PBS). The cells were incubated for 30 min on ice using the FITC-anti-human CD95 monoclonal antibody (clone UB2) or IgG 1 isotype control from Beckman Coulter (Fullerton, CA). Flow cytometry was performed with a Dako flow cytometer (Dako, Glostrup, Denmark).
Signal intensity was calculated by dividing median fluorescence obtained with the specific antibody by signal intensity obtained with the isotype control antibody (specific fluorescence index, SFI).
Detection of apoptosis by annexin V binding
Apoptotic cell death was analyzed by staining with FITC-labeled annexin V (BD Bioscience, Heidelberg, Germany). Glioma cells were treated as indicated, collected, washed with PBS, and resuspended in a buffer containing 10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2. Then annexin V-FITC and PI were added.
After incubation for 30 min, the cells were analyzed by flow cytometry (Dako CyAn ADP 7). Cells positive for annexin V binding and negative for PI staining were considered as early apoptotic. Cells positive for annexin V binding and positive for PI staining were considered as late apoptotic cells.
Growth and viability assay
The cells were seeded in 96 well plates and allowed to attach for 24 h. Cells were treated as indicated and cell density of attached cells was assessed by crystal violet staining. Briefly, the cell culture medium was removed and surviving cells were stained with 0.5% crystal violet in 20% methanol for 20 min at room temperature.
The plates were washed extensively under running tap water, air-dried and optical density values were read in an enzyme-linked immunosorbent assay (ELISA) reader (Mithras LB 940, Berthold technologies, Bad Wildbad, Germany) at a wavelength of 550 nm.
Immunoblot analysis
The general procedure has been described. 
Animal experiments
CD1
nu/nu mice were purchased from Charles River Laboratories (Sulzfeld, Germany).
The experiments were performed according to the German animal protection law.
For the intracranial glioma model, mice aged 6-12 weeks were anesthetized and placed in a stereotaxic fixation device (Stoelting, Wood Dale, IL). A burr hole was drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton syringe (Darmstadt, Germany) was introduced to a depth of 3 mm. 10 
Immunohistochemistry
For histology, 8 mm cryostat sections were stained with H&E. Cleaved caspase-3 (AF835; R&D Systems, Europe, Belgium) was detected by immunohistochemistry.
The tissue sections were pretreated with 3% H 2 O 2 in methanol to block endogenous peroxidase and boiled for 10 min in citrate buffer. Endogenous biotin activity was blocked with the DAKO biotin blocking kit (DAKOCytomation GmbH, Hamburg, Germany). Sections were blocked with 3% skim milk and 10% normal swine serum for 30 min each at room temperature. Primary antibodies were added and the tissue sections were incubated overnight at 4°C in a humidified chamber. Purified normal immunoglobulin G substituted for the specific antibody served as a negative control.
The sections were washed three times with PBS containing 0.05% Tween 20 (PBST). Biotinylated goat anti-rabbit secondary antibody (Vector Laboratories, Burlingham, CA) was added for 1 h. After three PBST washes, streptavidin peroxiase conjugate (Zymed, Berlin, Germany) was added and the tissue sections were incubated for 10 min, washed with PBST, and 3-amino-9-ethylcarbazole in N,N-dimethylformamide (Zymed) was added as a substrate. After further 10 min of incubation, the sections were finally washed with water. Terminal deoxynucleotidyl transferase mediated X-dUTP nick end labelling (TUNEL) was performed using the TUNEL-AP Kit (Roche, Basel, Switzerland). Neighbouring control sections were stained using Mayer's hematoxylin. All sections were cover-slipped and staining was assessed by light microscopy.
Statistics
Statistical significance was assessed by one-way analysis of variance between groups (ANOVA) and Bonferroni post hoc testing or student`s two-tailed t-test as indicated (SPSS 17, SPSS, Chicago, Illinois). Synergy of APO010 and TMZ was evaluated using the fractional product method. Here, "predicted values" correspond to an additive action of 2 compounds that can be compared to the observed effect. 
Results
APO010 is cytotoxic to human glioma cells
The human glioma cell lines studied here express different levels of CD95 as assessed by flow cytometry using an anti-human CD95 specific antibody (clone UB2). The SFI for the present culture conditions were 2.3 for U87MG, 2.1 for LNT-229 and 1.3 for LN-308. The SFI for SV-FHAS was 1.1.
The lower level of CD95 expression has been held responsible for the relative resistance of LN-308 cells to CD95-mediated apoptosis. 6 Accordingly, U87MG and LNT-229, but not LN-308, cells were highly sensitive to APO010. At equivalent concentrations, APO010 was more effective than sCD95L or CH11 in inducing cell death in both cell lines (Fig. 1A-C) . Accordingly, APO010 induced DEVD-amccleaving caspase activity in U87MG and LNT-229 cells (Fig. 1D-E) , but not in LN-308 cells (data not shown). Cell death induction involved the cleavage of caspases 8 and 3 and of PARP, and caspase and PARP processing were blocked by the broad spectrum caspase inhibitor, zVAD-fmk (Fig. 1F) . The induction of cell death by APO010 critically depended on the activation of caspase 8 since LNT-229 cells overexpressing crm-A, which selectively blocks caspase 8, were resistant (data not shown).
Cell death induction by APO010 was further characterized by flow cytometry using annexin V labelling for the assessment of apoptosis and PI staining for the detection of cell death. APO010 was more effective in inducing apoptosis than sCD95L or CH11, and the induction of cell death was blocked by zVAD-fmk. Consistent with the cell loss depicted in Fig. 1, U87MG and LNT-229 cells were sensitive ( Fig. 2A, B) whereas LN-308 cells were resistant (Fig. 2C) . Moreover, SV-FHAS astrocytes were resistant to APO010 (Fig. 2D ).
Further, we tested primary glioma cell cultures from 9 randomly selected glioblastoma patients. These ex vivo propagated cells were treated between passage 4 and 9 with either APO010, sCD95L or CH11. Again, APO010 was more effective in inducing apoptosis than sCD95L or CH11 as assessed by annexin V / PI labelling and flow cytometry (Table) . APO010 killed in a concentration-dependent manner more than 50% of the cells at a concentration of 1000 ng/ml in seven 
Cytotoxicity of APO010 critically depends on the expression of CD95
To assess the specificity of the cytotoxic activity of APO010, CD95 expression was silenced using siRNA in LNT-229 and U87MG glioma cells. Successful gene silencing was verified by flow cytometry 72 h following transfection (Fig. 3A) . Timecourse experiments confirmed a stable knock-down of CD95 between 72 and 96 h following transfection (data not shown). The knock-down of CD95 led to a significant reduction of sensitivity of both cell lines towards APO010-mediated cytotoxicity (Fig.   3B ). To sensitize LN-308 cells towards APO010, these cells were genetically modified to overexpress CD95 and subcloned. The clones LN308.CD95 K2 and K3
showed stable overexpression of CD95 as assessed by flow cytometry (SFI 7.0 and 14.4) and gained sensitivity towards APO010 (Fig. 3C ).
APO010 synergizes with TMZ in inducing glioma cell death
The next set of experiments was performed to evaluate additive or synergistic effects of APO010 and TMZ, the most commonly used drug for the treatment of glioblastoma. According to the fractional product method 24 , the combination of APO010 and TMZ had more than additive, that is, synergistic cytotoxic effects (Fig.   4A ). Resistance to TMZ alone is conferred by the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). 18 To assess whether the combination of APO010 and TMZ bypassed the protective function of MGMT, we cotreated MGMT-transfected cells with APO010 and TMZ. No synergy was observed under these conditions (Fig. 4B) , suggesting that the MGMT-sensitive effects of TMZ mediate synergy. Accordingly, when higher, equieffective concentrations for monotherapy with TMZ were employed in the MGMT-transfected cells, synergy was restored (data not shown). Moreover, preexposure of the MGMT-transfected cells to the MGMT inhibitor O6BG and subsequent coexposure to lower concentrations of TMZ and APO010 also resulted in synergistic induction of cell loss (Fig. 4C ). These data corroborated that no specific, MGMT-independent cascade triggered by TMZ facilitates APO010-induced apoptosis. Importantly, LN-308 cells, which are resistant to death receptor-mediated apoptosis, were sensitized by TMZ to APO010-mediated cell death (Fig. 4D) . However, since LN-308 cells are also relatively resistant to TMZmediated cell death 18 , a higher concentration of TMZ compared to LNT-229 cells was necessary to achieve this sensitization. Moreover, the synergy of TMZ and APO010 led to enhanced DEVD-amc-cleaving caspase activity in LNT-229 cells (Fig.   4E ).
APO010 induces glioma cell death in vivo and prolongs survival
Orthotopic human U87MG xenografts were established in nude mice as outlined in the Methods section and were confirmed to be associated with intracranial tumor growth as assessed by histology. APO010 was administered by stereotactic injection on days 7 and 14 after tumor cell implantation. The dose of 40 ng per single injection was determined from tolerability studies in preceding applications in non-tumor bearing mice. APO010 conferred a significant survival benefit. At 40 days after tumor cell implantation, the survival rate was 80% as opposed to 0% in control-treated animals (p < 0.01; student`s two tailed t-test). The median survival increased from 37 to 52 days (Fig. 5A) . The subsequent death of the mice in the APO010 treatment group was related to neurological symptoms following recurrence of tumor growth as assessed macroscopically. Systemic treatment was performed by i.p. injections of APO010 with the maximum tolerated dose of 0.015 mg/kg body weight three times per week following tumor inoculation until the mice had to be sacrificed due to the development of neurological symptoms. The survival of the mice in the treatment and PBS control group did not differ significantly (p = n.s.; student`s two tailed t-test) (Fig. 5B) .
Histological studies were performed on day 15 after tumor inoculation in i.c.-treated mice. H&E staining revealed minimal tumor burden in the APO010 group compared to controls (Fig. 5C a and b) . Apoptotic tumor cells were detected by TUNEL-staining ( Fig. 5C c and d) and immunohistochemistry for active caspase 3 ( Fig. 5C e and f) only in the APO010, but not the control group (Fig. 5C middle and lower panels) .
The failure of systemic application to limit tumor growth suggested insufficient APO010 delivery to the target. Accordingly, to assess intratumoral APO010, tumors were implanted and 6 mice per group were treated by a single i.p. or i.c. administration of APO010 or PBS as a control. Three mice per group were sacrificed 4 h and 3 mice 24 h following treatment. Tumor lysates were assessed for APO010 by immunoblot. APO010 was only detected in the tumors from mice injected i.c. with APO010, but not in the APO010 i.p. or the PBS control groups (Fig. 5D) . At 24 h (Fig. 5D, lower panel) , note a weak band in lane 3 and only background signal in lane 5. Equal protein loading was ascertained by Ponceau S staining (data not shown).
Discussion
This article reports on a further development in the field of death receptor targeting for malignant glioma. We find that APO010, a novel hexameric CD95 agonist 17 , is superior to either soluble CD95L or the agonistic CD95 antibody CH11 in killing CD95-expressing U87MG and LNT-229 glioma cells ( Fig. 1 and 2 ). Superior activity of APO010 over other CD95 agonists has previously been observed in leukemia and SKOV-3 ovarian cancer cells. 25, 26 The induction of cell death in glioma cells was specific in that it was receptor-mediated. In LN-308 cells, which express very little CD95, a significant induction of cell death was observed only for the highest dosis of APO010 ( Fig. 1C and 2C ) and LNT-229 cells overexpressing crm-A were resistant to APO010 (data not shown). Moreover, in contrast to human Apo2L/TRAIL, which failed to kill freshly isolated glioma cells 27 , activity of APO010 was also observed in various primary glioma cell cultures (Table) . The CD95 gene silencing in LNT-229 or U87MG cells abrogated, and the overexpression of CD95 in LN-308 cells conferred sensitivity of these cells (Fig. 3) . Therefore, the cell surface expression of CD95 is a prerequisite for the cytotoxic action of APO010 and the expression level of CD95 a gross indicator for the sensitivity. However, the susceptibility of the cell lines is likely modulated additionally by down-stream intra-cellular targets, e.g. caspases and In contrast, no synergistic effect of APO010 was demonstrated in vivo when combined with irradiation. 23 In view of a possible clinical application, we combined APO010 with TMZ, the current standard of care chemotherapy for glioblastoma.
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There was compelling evidence for synergy as assessed by the fractional product method and this synergy required the classical MGMT-sensitive cell death pathway triggered by TMZ (Fig. 4) . Sensitization of glioma cells towards Apo2L/TRAIL-mediated apoptosis by lomustine, another alkylating chemotherapeutic agent, involved the mitochondrial pathway and enhanced cytochrome c release.
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Another report demonstrated an upregulation of CD95 following treatment of U87MG cells with the O6-methylating agent N-methyl-Nnitro-N-nitrosoguanide by immunoblot in membrane extracts. 33 In this study, we did not observe an upregulation of CD95 on the cell surface by flow cytometry under conditions of synergistic killing in LN-308 cells (data not shown).
Local injection of APO010 conferred a significant survival benefit to glioma-bearing mice in the absence of relevant toxicity (Fig. 5) . APO010 was only active in vivo when administered locally, but not when given intraperitoneally. Assessment of tumors ex vivo revealed APO010 only in the i.c.-treated group, but not following i.p. injection (Fig. 5D ). This suggests that upon systemic treatment with the maximum tolerated dose, too little, if any, APO010 reaches the tumor. In general, the toxicity of the human APO010 in mice in vivo has been favourable compared with the mouse Jo2 antibody. When applied in BALB/c mice, 100 µg of Jo2 killed most of the mice and 10 µg killed half of the mice when given i.p.. The injection of up to 10 µg CH11 into s.c. growing tumors derived from SNB19 or SNB79 glioblastoma cell lines was tolerated, too, but did not alter tumor growth either.
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In the same study, mice were also injected up to 10 µg CH11 intravenously. A MTD was not formally determined in either study. 
